Terbogrel (INN[1]) is an experimental drug that has been studied for its potential to prevent the vasoconstricting and platelet-aggregating action of thromboxanes.

Terbogrel is an orally available thromboxane A2 receptor antagonist and a thromboxane A synthase inhibitor.

[2][3] The drug was developed by Boehringer Ingelheim.

A phase 2 clinical trial of terbogrel was discontinued due to its induction of leg pain.

[4]